Recruiting
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis - IM011-1105
Updated:
22 July, 2024
|
ClinicalTrials.gov
Gender(s)
Age Range
Location(s)
Recruiting
Inclusion Criteria: - Have been diagnosed with plaque psoriasis by a dermatologist - Newly initiating an eligible medication for enrollment (i.e., deucravacitinib, apremilast) - Actively enrolled in the CorEvitas Psoriasis Registry and have documented consent to allow copies of information from the registry be used for research purposes Exclusion Criteria: - Participation (current or planned) in an interventional clinical trial (does not include observational registry or study) - Restart of treatments with the study eligible therapies previously received at any time during the participants' treatment history
If you want to report a side effect, you can report directly to the Danish Medicines Agency via the website www.meldenbivirkning.dk
We recommend that you also contact BMS to report side effects.
Side effects and other reportable events are defined here
Report side effects or product quality complaints: Medical Information
466-DK-2200001